Key Points
- CeriBell CTO Raymond Woo sold 1,966 shares on May 21 at an average price of $18.00, generating about $35,388. The sale was tied to tax withholding from vesting equity awards, and he still owns 195,682 shares.
- This was part of a series of recent insider sales by Woo, who also sold more than 11,000 shares on both May 1 and April 1, and 8,087 shares on March 2.
- CeriBell reported mixed quarterly results, missing EPS expectations with a loss of $0.52 per share while revenue came in slightly above forecasts at $26.49 million. Analysts currently rate the stock a Moderate Buy with a consensus target price of $22.20.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) VP David Foehr sold 862 shares of the company's stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $18.80, for a total value of $16,205.60. Following the transaction, the vice president directly owned 37,751 shares in the company, valued at approximately $709,718.80. This represents a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
David Foehr also recently made the following trade(s):
- On Thursday, May 21st, David Foehr sold 987 shares of CeriBell stock. The shares were sold at an average price of $18.00, for a total value of $17,766.00.
- On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The shares were sold at an average price of $17.80, for a total value of $81,168.00.
CeriBell Trading Up 0.2%
CBLL opened at $18.80 on Wednesday. The stock has a market cap of $713.27 million, a price-to-earnings ratio of -11.53 and a beta of 0.99. The stock's 50 day moving average price is $19.09 and its 200-day moving average price is $19.24. CeriBell, Inc. has a one year low of $10.85 and a one year high of $24.33. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44.
CeriBell (NASDAQ:CBLL - Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.13). The business had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. On average, equities analysts forecast that CeriBell, Inc. will post -1.69 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of CBLL. Strs Ohio bought a new position in CeriBell in the first quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd grew its stake in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company's stock worth $28,000 after purchasing an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in CeriBell in the third quarter worth approximately $33,000. CWM LLC grew its stake in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company's stock worth $40,000 after purchasing an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after purchasing an additional 1,801 shares in the last quarter.
Analyst Upgrades and Downgrades
CBLL has been the topic of several research analyst reports. Weiss Ratings cut CeriBell from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, May 12th. Canaccord Genuity Group dropped their price objective on CeriBell from $28.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, May 12th. Finally, BTIG Research reissued a "buy" rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, CeriBell currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.20.
Get Our Latest Research Report on CeriBell
CeriBell Company Profile
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
